Toggle Main Menu Toggle Search

Open Access padlockePrints

The Newcastle University research output collection, currently available on ePrints, will shortly be moving to a new open repository platform, Figshare. To prepare for the data migration we have paused adding new content to ePrints, and will resume once the new repository is launched. During this time you will continue to have access to ePrints (but no new content will appear). We will share updates here when available.

Impact of Wilms’ tumor 1 gene (WT1) mutation on outcome of allogeneic hematopoietic-cell transplantation for acute myeloid leukemia: a retrospective multicenter cohort study from the ALWP/EBMT registry

Lookup NU author(s): Professor Matthew CollinORCiD

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

© The Author(s) 2025.We compared transplantation outcomes of AML patients with WT1 mutation (mWT1), identified by next-generation sequencing, to those of patients with wild-type WT1 AML (wtWT1). 703 patients were included, 50 with mWT1 and 653 with wtWT1. Patients with mWT1 were younger (median age: 45.6 vs. 56.4 years, p < 0.001), with a higher proportion of females (66% vs. 47.6%, p = 0.01), higher frequency of mutations in FLT3-ITD (38.3% vs. 21.7%, p = 0.01) and CEBPA (15.8% vs. 5.7%, p = 0.03). Donors were matched siblings in 30.6%, unrelated in 45.6%, and haploidentical in 22.1%. A higher percentage of mWT1 vs. wtWT1 patients received in vivo T-cell depletion (66% vs. 51%, p = 0.03) and 58% vs. 47.1% received myeloablative conditioning. 49 patients with mWT1 were matched to 127 wtWT1 patients in matched-pairs analysis. Outcomes (mWT1 vs. wtWT1) were not significantly different: relapse (2 y: 28.8% vs. 30.4%, HR: 1.14, p = 0.64), NRM (2 y: 15.5% vs. 9.9%, HR: 1.41, p = 0.49), LFS (2 y: 55.7% vs. 59.6%, HR: 1.21, p = 0.39), OS (2 y: 65.4% vs. 73.3%, p = 0.66), and chronic GVHD (2 y:24.3% vs. 25.4%, p = 0.95). In conclusion, WT1 mutation did not influence transplantation outcomes of AML patients in CR1.


Publication metadata

Author(s): Nagler A, Esteve J, Galimard J-E, Sanz J, Poire X, Collin M, Maertens J, Huang H, Itala-Remes M, Halahleh K, Pascual Cascon MJ, Chiusolo P, Griskevicius L, Kaare A, De Becker A, Jindra P, Perez-Simon JA, Bazarbachi A, Brissot E, Ciceri F, Mohty M

Publication type: Article

Publication status: Published

Journal: Bone Marrow Transplantation

Year: 2026

Volume: 61

Pages: 44-50

Print publication date: 01/01/2026

Online publication date: 16/10/2025

Acceptance date: 22/09/2025

Date deposited: 10/12/2025

ISSN (print): 0268-3369

ISSN (electronic): 1476-5365

Publisher: Springer Nature

URL: https://doi.org/10.1038/s41409-025-02727-7

DOI: 10.1038/s41409-025-02727-7

Data Access Statement: AN, JEG, and MM had full access to all the data in the study (available upon data- specific request)


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
Tel Aviv University

Share